Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX02 Gemtuzumab ozogamicin
D03259 Gemtuzumab ozogamicin (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Gemtuzumab Ozogamicin
D03259 Gemtuzumab ozogamicin (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
423 Antibiotics
4239 Others
D03259 Gemtuzumab ozogamicin (USAN); Gemtuzumab ozogamicin (genetical recombination) (JAN); Gemtuzumab (INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D03259 Gemtuzumab ozogamicin
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD33 (SIGLEC3)
D03259 Gemtuzumab ozogamicin (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03259
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03259
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03259
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03259
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03259
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D03259
